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Introduction: Current ESC guideline supported invasive treatment of non-ST elevation acute
coronary syndrome (NSTE-ACS) is guided by GRACE risk model.
Objective: The aim of this study was to determine whether the percutaneous coronary
intervention treatment in (NSTE-ACS) ameliorates the long-term mortality assessed by
GRACE risk score.
Methods: We conducted a retrospective study of a consecutive sample of 680 patients with
(NSTE-ACS) treated by PCI in Heart Center of Semmelweis University. The GRACE risk score
was calculated for each patient at admission. The mean of relative risk in each group was
assessed and compared with the long-term clinical outcomes (observed 6-month mortality).
Results: The mean of calculated GRACE amounts to 1.6% for low risk patients, 5.0% for
medium risk patients, and 21.3% for patients with high risk. In contrast, the observed risk of
6-month death was 0.42% for low risk patients, 1.1% for medium risk patients, and 12.6% for
patients with high risk. The difference between assessed and observed 6-month mortality in
high risk and medium risk groups was signiﬁcant (medium risk p = 0.004; high risk
p = 0.0097). Observed risk of death in low risk patients was also lower, but not signiﬁcant
than assessed risk.
Conclusion: The risk of death in patients with NSTE-ACS treated in a high volume center is
signiﬁcantly lower than predicted by the GRACE risk model. Our results suggest that
percutaneous coronary intervention treatment guided by the GRACE risk model in medium
and high risk patents with (NSTE-ACS) provides the greatest clinical beneﬁt.
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Introduction
At least 70% of acute coronary patients are classiﬁed as those
with either unstable angina or non-ST segment elevation
myocardial infarction (NSTE-ACS) [1,2]. Despite secondary
prevention including pharmacological treatment [3] and
optimal cardiac rehabilitation [4], the long-term outcomes of
patients with unstable angina or NSTEMI are equal or worse [5–
9] than the outcomes in ST-segment elevation myocardial
infarction [10]. These consequences are a result of by increased
age and are further evidence of comorbidity such as diabetes
mellitus, chronic kidney disease, previous myocardial infarc-
tion, coronary artery bypass graft surgery or advanced
coronary disease. Consequently the risk stratiﬁcation plays
a key role in the management of NSTE-ACS [11–19]. The Global
Registry of Acute Coronary Events (GRACE) risk model enables
professionals to assess the risk of death and it also provides a
Table 1 – Baseline clinical characteristics of patients in
Heart Center of Semmelweis University (HC-SE) and
GRACE NSTE-ACS study (GRACE).
Patient characteristics HC-SE
(n = 690)
GRACE
(n = 23,825)
Age (years) 67 67
Male (%) 69 65
Hypertension (%) 82* 64
Hypercholesterolemia (%) 48 51
Diabetes mellitus (%) 34* 27
Myocardial infarction (%) 51* 37
Percutaneous coronary intervention (%) 22 20
Coronary artery bypass graft (%) 12* 17
Values are n (%). HC-SE, Heart Center Semmelweis University;
GRACE, Global Registry of Acute Coronary Events.
* p < 0.05.
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The aim of the study was to determine whether the
percutaneous coronary intervention treatment in NSTE-ACS
could improve the long-term mortality according to the
estimated GRACE risk score.
Methods
Study population
The study population included 690 consecutive patients with
NSTE-ACS treated by PCI in the Heart Center of Semmelweis
University, Budapest, Hungary. Eligible patients were at least
18 years old and were admitted to the hospital with a
presumptive NSTE-ACS which was veriﬁed. Each one of them
was treated with percutaneous coronary intervention.
Patient stratiﬁcation
The cohort of the present study (n = 690) was stratiﬁed on the
basis of predeﬁned cut-off points of the GRACE risk score into
low, medium and high risk groups. The GRACE risk model is
composed of the following predictor variables on presentation:
age, heart rate, systolic blood pressure, cardiac arrest, Killip
class, creatinine, ST segment deviation and biomarker status
[27]. Points are scored according to the set variables for each
element, and the sum of the points equates to the GRACE risk
score. All of the risk groups were divided into further
subgroups by age: under 65 years, between 65 and 75 years,
and above 75 years.
Statistics
Comparison of the predictor variables between the interna-
tional GRACE patient population and the patients treated in
the Semmelweis University Heart Center was made by x2 test.
The mean of the individual GRACE risk scores was calculated
in each risk group. x2 test was used for comparison of assessed
and observed risks of death. All calculations were done with
Excel 2009 (Microsoft Inc., Seattle, USA).Results
Baseline clinical characteristics of 690 patients with NSTE-ACS
treated with PCI in the Heart Center of Semmelweis University
were compared to the characteristics of the population of
GRACE NSTE-ACS registry in Table 1. Patients of our study
population were more likely to have a history of hypertension,
diabetes mellitus and previous myocardial infarction.
According to the calculated GRACE risk score, 184 patients
were assigned to the group with high risk, 266 patients to the
group with medium risk and 251 patients to the group with low
risk. A total of 27 patients died within 6 months after PCI, 22 of
them showed high risk, 3 medium and only 1 patient was in
the low risk group. The observed relative risk of 6-month
mortality amounts to 12.6% for high risk, 1.1% for medium risk,
and 0.4% for low risk patients.
The difference between assessed and observed 6-month
mortality in the high risk group was statistically signiﬁcant
( p = 0.03). Observed mortality in the low and medium risk
group was not signiﬁcant, but it shows a downward tendency.
The patients between aged 65 and 75 years belonging to the
medium risk subgroup and patients aged above 75 years
belonging to the high risk subgroup had signiﬁcantly lower
observed mortality than assessed risk of death (Fig. 1).
Discussion
The results of the present study show that the risk of death in
patients with NSTE-ACS treated with PCI in a high volume
center was signiﬁcantly lower than predicted by the GRACE
risk model. After PCI the observed mortality decreased in each
risk group and subgroup compared to the assessed risk of
death by GRACE score, signiﬁcantly in patients with high risk
(12.6% compared to 21.3%) and in patients between aged 65
and 75 years belonging to the medium subgroup (0.7%
compared to 5.04%). The observed mortality in patients
belonging to the medium risk group (1.1%) reached the level
of the low risk group assessed by the GRACE risk model (1.6%).
In point of mortality, patients in the medium risk group treated
with PCI have fallen into the group with low risk. While our
low risk group 
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Fig. 1 – Assessed and observed 6-month mortality in low,
medium and high risk groups. *Indicates statistically
significant difference ( p < 0.05).
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 3 3 3 – e 3 3 6 e335study population was more likely to have comorbidity (such as
hypertension, diabetes mellitus or previous myocardial
infarction) than the population studied in GRACE trial, after
all the observed risk of death was lower.
Our results suggest that percutaneous coronary interven-
tion treatment guided by expert cardiologists in a high volume
interventional center provides the greatest clinical beneﬁt in
medium and high risk patients with NSTE-ACS assessed by the
GRACE risk model.
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